SEC Form 4 · accession 0001144204-17-058399
BRAINSTORM CELL THERAPEUTICS INC. · BCLI
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Uri Yablonka
Officer — EVP and Chief Business Officer · Director
Period of report
Nov 10, 2017
Accepted (ET)
Nov 13, 2017 · 4:37 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001137883
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $0.75 | Nov 10, 2017 | A | 13,333 | A | Dec 10, 2017 | Nov 10, 2027 | Common Stock | 13,333 | 13,333 | D |
Explanation of responses
- F1Option vests and becomes exercisable in 12 consecutive, equal monthly installments commencing on December 10, 2017 until fully vested and exercisable on November 10, 2018, provided that the reporting person remains a director of Brainstorm Cell Therapeutics on each vesting date.